(Total Views: 387)
Posted On: 10/02/2025 12:58:20 AM
Post# of 157631
With all of the theories on why we aren't enrolling quickly I'm surprised that no one has stated the obvious: Our inclusion/exclusion criteria is extensive. I asked ChatGPT (I know, I know but if you have better data, please share) what percentage of all CRC patients might realistically meet our criteria. I'll share the answer below, but first I want to remind everyone, this inclusion/exclusion criteria was set by the company to optimize the patient pool for our drug in this trial based on the basket trial results.
On top of the below ChatGPT opinion of potential candidates, you have determine what percentage of those patients having already failed multiple lines of treatment are even willing to enroll. One of my uncles has CRC and just underwent his first real treatment line (just finished surgery) and he is in a ton of pain. By 3rd line a lot of these people may have given up so as to enjoy what little life they have left. Here are the results from ChatGPT:
Rough calculation
Start with 100 mCRC patients:
Heavily pretreated: ~65
MSS only: 85% → ~55
CCR5-positive: ~35% → ~19
ECOG 0–1 + organ function: ~45% → ~9
Exclusions: lose ~15% → ~8
➡️ About 8% of metastatic CRC patients might realistically qualify.
If you take all colorectal cancer patients (localized + metastatic), it’s closer to 3–4% of total CRC.
✅ Bottom line:
Roughly 5–10% of metastatic colorectal cancer patients (and ~3–4% of all CRC patients) would be expected to meet these trial inclusion/exclusion criteria.
On top of the below ChatGPT opinion of potential candidates, you have determine what percentage of those patients having already failed multiple lines of treatment are even willing to enroll. One of my uncles has CRC and just underwent his first real treatment line (just finished surgery) and he is in a ton of pain. By 3rd line a lot of these people may have given up so as to enjoy what little life they have left. Here are the results from ChatGPT:
Rough calculation
Start with 100 mCRC patients:
Heavily pretreated: ~65
MSS only: 85% → ~55
CCR5-positive: ~35% → ~19
ECOG 0–1 + organ function: ~45% → ~9
Exclusions: lose ~15% → ~8
➡️ About 8% of metastatic CRC patients might realistically qualify.
If you take all colorectal cancer patients (localized + metastatic), it’s closer to 3–4% of total CRC.
✅ Bottom line:
Roughly 5–10% of metastatic colorectal cancer patients (and ~3–4% of all CRC patients) would be expected to meet these trial inclusion/exclusion criteria.
(11)
(0)
